ERBB2 and central nervous system neoplasm: HER2-specific CAR-T cells were repeatedly administered by intraventricular injection to children and young adults with recurrent or refractory HER2-expressing CNS tumors at doses ranging from 1 × 107 to 1 × 108 cells [131].